A high-quality pharmaceutical franchise with a Piotroski F-Score of 7 out of 9, 135% free cash flow conversion, and four consecutive earnings beats averaging 14% above estimates is priced with just 0.9% headroom to the price target; momentum is at the minimum threshold with falling on-balance volume, and a 448% dividend payout ratio cannot be sustained from current earnings — the setup favors holding an existing position rather than deploying new capital.
Thesis pillars
- Consistent Earnings Beat Quality→Stable
- Fully Priced Limited Room→Stable
- Dividend Payout And Leverage Strain→Stable
- +1 more pillar — see the Why tab for full reasoning
Bristol-Myers Squibb Company (BMY) Stock Analysis
Breakout setup · Catalyst-Driven edge
Healthcare · Drug Manufacturers - General
Sell if holding. Analyst target reached at $58.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%).
Bristol-Myers Squibb develops and markets oncology, hematology, immunology, and cardiovascular medicines in a single segment, generating $48.2 billion in total revenues in 2025, with 69% from the United States. The company sells principally to wholesalers, distributors, and... Read more
Sell if holding. Analyst target reached at $58.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%). Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. Score 5.7/10, moderate confidence.
Passes 6/8 gates (positive momentum, clean insider activity, no SEC red flags, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and news legal. Suitability: conservative.
About Bristol-Myers Squibb Company
About Bristol-Myers Squibb Company
Bristol-Myers Squibb generated $48.2 billion in total revenues in 2025, with Eliquis (apixaban)—the company's most prominent product—facing loss of U.S. market exclusivity in 2028 under patent settlements with generic manufacturers, while EU apixaban composition of matter patents and related SPCs expire in November 2026. The company reports in a single segment spanning oncology, hematology, immunology, and cardiovascular therapeutics, with 69% of revenues from the United States and 29% from international markets.
BMS markets biologics including Opdivo, Orencia, Yervoy, Reblozyl, and Opdualag; oral therapies including Eliquis, Revlimid, Pomalyst, Sotyktu, and Camzyos; and CAR-T therapies Breyanzi and Abecma, sold principally through wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies. As of January 31, 2026, U.S. generic lenalidomide licenses under Revlimid patent settlements are no longer volume-limited. Pomalyst faces U.S. generic entry in the first quarter of 2026, and the HHS set a maximum fair price for Pomalyst under the IRA effective January 1, 2027. Manufacturing operates in the U.S., Puerto Rico, the Netherlands, Ireland, and Switzerland, with CAR-T and radiopharmaceutical therapies presenting novel supply-chain challenges including reliance on third-party suppliers still in development. In October 2025, FDA issued draft guidance to streamline biosimilar development timelines, which could accelerate biosimilar competition for BMS biologics.
Show full overview
BMS's exposure to IRA price-setting is already concrete: HHS announced a maximum fair price for Eliquis effective January 1, 2026 under Medicare, for Pomalyst effective January 1, 2027, and selected Orencia for negotiation beginning 2028. In December 2025, BMS separately signed a U.S. Government Agreement under which it agreed to provide Eliquis free to Medicaid beginning January 1, 2026, and to offer Sotyktu, Zeposia, Reyataz, Baraclude, and Orencia to cash-paying patients at approximately 80% off list prices, in exchange for tariff relief through January 2029. The company remains subject to pricing mandates outside the United States, and the IRA framework could expand to cover additional BMS products in future selection rounds.
See also: Healthcare · Drug Manufacturers - General
From Bristol-Myers Squibb Company's most recent 10-K filing, extracted June 10, 2026.
Recent developments
updated 2026-07-05Recent Developments — Bristol-Myers Squibb Company
Latest news
- NEWS Do Wall Street Analysts Like Bristol-Myers Squibb Stock? - Yahoo Finance — Yahoo Finance neutral
- NEWS Earnings To Watch: Bristol-Myers Squibb (BMY) Reports Q1 Results Tomorrow - StockStory — StockStory neutral
- NEWS Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts - Yahoo Finance — Yahoo Finance positive
- NEWS Bristol-Myers Squibb: Vestmo Stock of the Week - Barron's — Barron's positive
- NEWS Cantor Fitzgerald raises Bristol-Myers Squibb stock price target to $54 - Investing.com — Investing.com positive
Generated 2026-07-05T16:50:23Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographicUnited States69%10-K Item 1: 'United States| 69 | %...Total Revenues| $| 48,194'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Growth below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $58.02 — A.R:R is negative (-0.3) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: United States (69.0%). Chart setup: Golden cross, above all MAs, RSI 57, MACD bullish. Prior stop was $55.25. Score 5.7/10, moderate confidence.
Take-profit target: $57.06 (-1.8% upside). Prior stop was $55.25. Stop-loss: $55.25.
Concentration risk — Geographic: United States (69.0%); Analyst target reached - limited upside remaining; Leverage penalty (D/E 2.3): -1.5.
Bristol-Myers Squibb Company trades at a P/E of 16.3 (forward 9.4). TrendMatrix value score: 6.8/10. Verdict: Sell.
36 analysts cover BMY with a consensus score of 3.5/5. Average price target: $63.
What does Bristol-Myers Squibb Company do?Bristol-Myers Squibb develops and markets oncology, hematology, immunology, and cardiovascular medicines in a single...
Bristol-Myers Squibb develops and markets oncology, hematology, immunology, and cardiovascular medicines in a single segment, generating $48.2 billion in total revenues in 2025, with 69% from the United States. The company sells principally to wholesalers, distributors, and specialty pharmacies globally, with key products including Eliquis, Opdivo, and Orencia facing patent cliffs and IRA-driven pricing pressures.